Why was levobupivacaine taken off the market?

Price vs Demand? My guess would be lack of sustained need / demand for it. I suspect that despite advertised (and proven) better cardiovascular side effects profile the gain might have been perceived by clinicians to be too small compared to difference in price. It's my guess, not based on personal experience in procuring the drugs / working on committees. There must be HealthTap colleagues with more expertise.